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Abstract
Success in treating patients with atypical parkinsonism remains exceedingly low. It is
particularly important for both neurologists and general practitioners to have a guideline
in the actual possible cure options. This study reviews the limited available literature
reporting  treatment  trials  about  treatment  in  parkinsonism.  Various  therapeutical
approaches have been tried with rasagiline, immunoglobulin, autologous mesenchy‐
mal stem cells, davunetide, lithium, and tideglusib. Recently, transdermal rotigotine
(RTG) has been proposed for the treatment of atypical parkinsonism, as well as deep brain
stimulation (DBS) of the pedunculopontine nucleus (PPN) alone or combined with globus
pallidus internus (Gpi) stimulation. The outcomes reviewed here highlight the need for
the development of randomized, placebo-controlled trials to validate outcomes about
rotigotine, DBS, and all other new therapies directed at altering the underlying biologi‐
cal mechanisms involved in the disease process.
Keywords: atypical parkinsonism, treatment options, pharmacological intervention,
deep brain stimulation, diagnosis
1. Introduction
Progressive  supranuclear  palsy  (PSP),  corticobasal  degeneration  (CBD),  multiple  system
atrophy (MSA), Parkinson’s disease with dementia (PDD), and dementia with Lewy bodies
(DLB) are usually indicated as atypical parkinsonian syndromes (APS). Anyway, each of that
syndrome is characterized by peculiar anatomo-pathological picture [1–5]. Up to date, the
amount of pathophysiological data available regarding APS has progressively grown in the
past two decades. Nonetheless, the etiology of APS is still under investigation and effective
treatments are lacking [6,7]. Various therapeutical approaches have been tried with rasagi‐
line, immunoglobulin, autologous mesenchymal stem cells, davunetide, lithium, and tideglu‐
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sib [8]. Recently, the transdermal rotigotine (RTG) has been proposed for the treatment of atypical
parkinsonism [9–11], as well as deep brain stimulation of the pedunculopontine nucleus (PPN)
alone or combined with globus pallidus internus (Gpi) stimulation [12]. This study reviews the
limited available literature reporting treatment trials. The outcomes reviewed here highlight
the need for the development of novel therapies directed at altering the underlying biological
mechanisms involved in the disease process.
2. Materials and methods
This study reviews all the limited available literature reporting treatment trials about treatment
in atypical parkinsonism.
3. Clinical features
Diagnosis of AP has been performed in accordance with the primary diffuse tips and medi‐
cal criteria [13–20]. PSP is characterized by vertical gaze abnormalities, early falls, postural
instability, and presenile cognitive impairment. PSP has two principal clinical forms: classi‐
cal PSP (or Richardson’s syndrome) and PSP-parkinsonism (PSP-P). Respect to the classical
form, PSP-P is characterized by the presence of tremor and an inconstant clinical response to
levodopa. The classical CBD phenotype includes apraxia, cortical sensory loss, alien limb, as
well as dystonia and myoclonus. MSA patients usually show a mix of cerebellar and pyrami‐
dal signs, parkinsonism, and autonomic dysfunction. The predominant phenotype at onset of
MSA allows the classification into MSA-parkinsonism or MSA-cerebellar form. The diagno‐
sis of PD was made following previously published criteria [21]. Only subjects with idiopath‐
ic PD were enclosed within the present study in order to get a homogeneous sample study
population [22]. So, patients had unilateral onset and development of parkinsonian signs, two
of the three cardinal signs among akinesia, rigidity, and postural abnormalities and resting
tremor. A superb response to a dopaminoagonist treatment was a strong criterion. In the
Parkison-dementia group, patients with idiopathic PD, who developed cognitive decline after
a year of the onset of parkinsonism, were included. On the contrary, in Lewy Body Demen‐
tia (LBD) group, patients with cognitive impairment appeared within 1 year after the onset of
movement disorders were included Moreover, in this group patients with Rapid Eye
Movements (REM) sleep behavior disorders, vivid dreams, hallucinations and postural
instability have been enclosed [22].
4. Results
4.1. Current pharmacological chances in APS
Table 1 summarizes the most important clinical trials aiming to find a drug therapy for APS.
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Authors Disease Treatment Duration Outcomes
Poewe et al. [23] MSA Rasagiline 48 weeks No improvement
Novak et al. [24] MSA Intravenous immunoglobulin 6 months Improvement
Lee et al. [25] MSA-cerebellar
type
Autologous mesenchymal
stem cells
12 months Improvement
Hoglinger et al. [35] PSP Tideglusib 12 months Improvement
www.allontherapeutics.
com, 2012
PSP Davunetide 52 weeks No improvement
Stamelou et al. [40] PSP CoQ10 6 weeks Improvement
Moretti et al. [9–11] MSA-PSP-
CBD-LBD
Transdermal rotigotine 24 months Improvement
Servello et al. [12] PSP DBS of PPN 12 months Improvement
Table 1. Synopsis of the main clinical trials for the treatment of atypical parkinsonism.
The monoamine oxidase-B inhibitor rasagiline with the dosage of 1 mg/day has been as‐
sessed in a randomized, placebo-controlled clinical trial for 48 weeks in 174 patients with
possible or probable MSA-parkinsonism type. The total Unified Multiple System Atrophy
Rating Scale (UMSARS) score did not found significant improvements in the treated when
compared to placebo groups [23].
A monthly infusions of 0.4 g/kg intravenous immunoglobulin for 6 months in seven patients
with MSA found significantly improved UMSARS part I (activities of daily living) and II
(motor functions) score. A verification study has been programmed [24] to validate the anti-
inflammatory approach.
Injections of autologous mesenchymal stem cells (MSCs) in 33 patients with probable MSA-
cerebellar compared with placebo demonstrated a smaller increase in total and part II
UMSARS scores in the MSC group. Anyway, a careful evaluation of the exact efficacy of the
staminal cells is under investigation [25].
Due to the dangers of postural instability in MSA from orthostatic hypotension, considera‐
ble attention has been directed toward blood pressure control. A synthetic norepinephrine
precursor was tested in 10 patients with MSA in a randomized, double-blind, placebo-
controlled study, resulting in an increase in supine and upright blood pressure [26,27].
Moreover, the droxidopa has been evaluated in a phase III clinical trial in order to assess the
efficacy in orthostatic hypotension, and recently FDA approved its clinical use (http://
www.medscape.com/viewarticle/820786). As about other autonomic symptoms, oxybutynin
or tolterodine can be helpful for neurogenic bladder and desmopressin can be helpful for
nocturnal polyuria, whereas sildenafil may be efficacious in erectile dysfunction, but can
dramatically worsen postural hypotension (Stamelou and Bathia). Recent large controlled
studies with rasagiline and rifampicin have shown no neuroprotective effect [23,28].
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In regard to PSP and CBD, in clinical practice, treatment options are limited to a levodopa
trial (up to 1 g/d) and amantadine for parkinsonism and gait disturbance as well as val‐
proate or levetiracetam for myoclonus [29]. Although not sufficiently studied, botulinum toxin
injections can be helpful to relieve dystonic spasms of the hand or to treat levator inhibition
[30]. Early clinical trials in PSP employed drug treatment to correct alterations in the dopami‐
nergic, cholinergic, and gamma-amino butyric acid (GABA)ergic pathways and produced
limited evidence of benefit. Trials with both physostigmine and donepezil were employed
with a poor response in memory as well as motor function [31,32]. As about GABAergic
agonists, trials with zolpidem [33] and gabapentin [34] found, respectively, transient improve‐
ment in eye movements and inhibitory frontal function. Anyway, these trials were limited by
small sample size and little evidence of a long-term benefit of the treatment.
Progressive Supranuclear Palsy Rating Scale (PSPRS) and the Schwab and England Activi‐
ties of Daily Living (SEADL) did not show significant outcomes in a multinational random‐
ized, double-blind, placebo-controlled trial in which 313 patient with PSP received
davunetide 30 mg twice daily or placebo (press release December 18, 2012 by Allon Thera‐
peutics, www.allontherapeutics.com).
The inhibitors of glycogen synthase kinase-3 (GSK-3) such as lithium or tideglusib have been
administered in PSP or CBD patients in two distinct trials. The lithium trial (ClinicalTrials.gov;
identifier NCT00703677) a patient with PSP ended before the natural time because the drug
was not tolerated. The tideglusib trial did not show significant improvement between the high-
dose, low-dose, and placebo groups in the final clinical evaluation [35].
Methylene blue derivatives are inhibitors of tau protein aggregation. These agents could be a
rational treatment for PSP and CBD. Anyway, the most advanced strategies for reducing tau
protein are immunologic approaches targeting different tau epitopes [36]. Moreover, passive
immunization approaches, which act through anti-tau monoclonal antibody directed against
various tau epitopes, were shown to block seeding activity and improve cognitive deficits in
transgenic mice [37].
Microtubule-stabilizing agents are also explored as potential therapies compensating the loss
of tau protein function in PSP and CBD. In particular, taxanes, a class of cancer drugs and a
related class of compounds called epothilones, are now being investigated as tau-related
neurodegeneration. The epothilone D was found to improve axonal microtubule density and
improved spatial learning in treated mice [38,39]. It has been suggested that mitochondrial
dysfunction may contribute to pathogenesis of atypical parkinsonisms. This evidence has led
to an interest in replacing the coenzyme Q10 (CoQ10), a component of the complex I of the
mitochondrial chain. A small, double-blind, placebo-controlled, randomized trial involving
21 PSP patients treated with CoQ10 for 6 weeks has shown improvement in PSPRS scores,
frontal assessment battery scores, and occipital energy when compared with placebo [40].
Currently, a large phase III trial with CoQ10 in PSP patients for 12 months is underway.
As about the LBD, the cholinergic deficit that affects in an important way these patients could
benefit from the cholinesterase inhibitors; hallucinations, neuropsychiatric symptoms, and
psychosis are all reduced in LBD [41].
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In a large, randomized, double-blind controlled trial with 120 LBD patients over 20 weeks,
rivastigmine treatment resulted in reduction of apathy, delusions, anxiety, and hallucina‐
tions, as well as improvements in cognitive assessment [42]. Furthermore, a 3-week post-
treatment follow-up has also shown better Neuropsychiatric Inventory (NPI) scores [43]. A
recent multicenter trial in Japan has administered donepezil to 140 patients with LBD showing
clinical, cognitive, and behavioral improvement when compared to placebo [44].
Recently, the effect of memantine, an NMDA-receptor antagonist, has been evaluated in two
clinical trials [45,46] in patients with both LBD and PDD. Although some clinical benefits have
been reached, the effect of memantine remains inconclusive.
Atypical antipsychotic agents such as quetiapine are recommended because of the risk of
extrapyramidal side effects in patients with LBD. Clonazepam at low dosage could be used in
REM sleep behavior disorder. As about parkinsonian disorders, levodopa should be admin‐
istered instead of dopaminergic agents with a particular care to the aggravation of psychotic
symptoms.
4.2. Transdermal RTG as treatment option for atypical parkinsonian syndrome
Transdermal RTG seems to be effective and well tolerated in patients with APS. Recent
studies [9–11] show significant improvement in UDPRS-III scores, maintained along the course
of the 248 months follow-up. Only seven patients were dropped out, and 15 patients were
affected by adverse events. In this study, behavioral or psychiatric adverse events and ICDs
were not found. Moreover, results also show a reduction in NPI scores that became signifi‐
cant at the last follow-up evaluation (T18). Finally, during the study the patients did not suffer
from congestive heart failure. These results confirm previous evidences obtained in patients
with idiopathic Parkinson’s disease showing positive effect on motor control and behavioral
disturbances [47–55] as well as a good safety of RTG [56]. On the whole, these outcomes
highlight that transdermal RTG should be considered as a therapeutic option for the treat‐
ment of atypical parkinsonism.
4.3. Deep brain stimulation in PSP
In a recent study [12], three patients with PSP were submitted to the deep brain stimulation of
the pedunculopontine nucleus (PPN). A reduction of falls and an amelioration of postural
balance were observed. The patients required less assistance for daily living activities. The
clinical improvement was, however, not fully reflected in the evaluating scales. The mean
PSPRS percentage decrease was of 26.3% (SD = 8.3) at the 12-month follow-up visit for the three
patients. The diversity between the reported improvement and the PSPRS might be due to the
phenomenological diversity of PSP, not fully captured by the PSPRS, and repeated sched‐
uled postoperative evaluations are necessary to capture objectively the overall clinical
improvement. That the greatest PSPRS percentage decrease (35.7%) was seen in the double-
implanted GPi-PPN patient is possibly due to the improvement of the concomitant ameliora‐
tion of his or her dystonic state. It remains of course speculative in light of a single case if this
better clinical outcome seen in the GPi-PPN patient is reflection of an increased synergic effect
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of PPN and GPi secondary to stimulation, bearing in mind the strong connectivity between
the basal ganglia and the PPN. An interesting observation was related to the stimulation
parameters; we started with low-frequency stimulation, which was increased progressively
to 130 Hz without noticing a significant change in clinical presentation.
4.4. Supportive therapies
The palliative therapies are highly recommended in APS patients. An assortment of physical,
occupational, and language therapies should be considered, paying attention to the most
invalidating symptom, that is, apraxia. If the risk of falls and postural instability become
prevailing symptoms, a wheelchair has to be suggested and should be advised to patient and
family. This acknowledgment can be shockingly testing and troublesome. Numerous families
see the utilization of a wheelchair as a marker of the last loss of the capacity to ambulate and
stay free. They should be persuaded that in addition to the fact that this is vital for the well-
being of the patient, the wheelchair can give a more prominent level of flexibility than the
constrained portability given by the patient’s attempts to try to deambulate. At long last, it is
vital to screen and support the prosperity of the caregivers. The especially troublesome mix of
serious motor inability with cognitive and behavioral aggravations increases the risk of an
overwhelming burnout.
4.5. Future treatment options
Different approaches such as “regenerative” or “restorative” (e.g., stem cells and trophic
factors) are desirable to provide advance in the field of disease-modifying therapy. Trials of
“neuroprotective” therapies are actively being planned or have been implemented (e.g., a trial
of riluzole for PSP and multiple system atrophy has been initiated in Europe). Further
discussion and evaluation of the best endpoints for clinical trials in these disorders are an
important priority. One of the major obstacles to the design of the necessary clinical trials is
the accuracy of clinical diagnosis. This finding emphasizes the need for developing biologi‐
cal markers for these neurodegenerative disorders. The similarities in the underlying neuro‐
pathology and molecular biology of these disorders suggest that critical advances in this field
will equally impact on the treatment outcomes [1].
5. Conclusions
Up to date, the possibilities of the APS care are without no doubt very low. Two main goals
are to achieve: the better understanding of the pathogenic mechanisms and the improve‐
ment of both symptomatic and disease-modifying treatments through controlled clinical trials.
In the near future, every effort should be made to give hope to patients and caregivers whose
number will not decrease.
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